Isobolographic Analysis in Mice of the Interaction of Gabapentin and Nortriptyline in Relieving Orofacial Pain

Aims: To evaluate the nature of the antinociceptive interaction of systemic administration of a combination of the anticonvulsant gabapentin with the antidepressant nortriptyline, by isobolographic analysis in the formalin orofacial pain test of mice. Methods: The study was carried out in 168 male CF-1 mice weighing 30 g, and the protocol was to test each drug (at dosages of 1, 3, 10, 30, and 100 mg/kg of gabapentin and 0.1, 1, 3, 10, and 30 mg/kg of nortriptyline; ip) alone and in combination. The isobolographic assay has two phases: phase 1 corresponds to the 5-minute period starting immediately after the formalin injection and reflects a tonic acute pain due to peripheral nociceptor sensitization; phase 2 is recorded as the 10-minute period starting 20 minutes after the formalin injection and reflects an inflammatory pain state. Results were analyzed by Student t test for independent means. Results: Gabapentin was 1.61 times more potent in phase 2 than in phase 1, and nortriptyline 1.37 times more potent in phase 2 than in phase 1. The combination of both drugs was synergic, with an index of interaction of 0.134 and 0.148 for phase 1 and phase 2, respectively. Differences in the pharmacological profiles of gabapentin and nortriptyline could underlie the synergism of the two drugs. Conclusion: The findings of this study are important, because they are concordant with some clinical studies and also raise the possibility of potential clinical advantages of combining gabapentin and nortriptyline in pain management, since the low doses of the components may potentially have a lower incidence of adverse reactions.

gabapentin; isobolographic analysis; nortriptyline; orofacial pain; synergism

1. Sarzi-Puttini P, Vellucci r, Zuccaro SM, cherubino P, Labianca r, fornasari D. The appropriate treatment of chronic pain. clin Drug investig 2012;32(suppl 1):21–33.

2. clauw D, Mccarberg BH. Managing chronic pain with nonopioid analgesics: a multidisciplinary consult. am J Med 2012;125:S1–S9.

3. Pasternak GW. Preclinical pharmacology and opioid combinations. Pain Med 2012;13(suppl 1):S4–S11.

4. Backonja M. Symptomatic treatment of chronic neurophatic pain with gabapentin—clinical practice and research prospective. curr neuropharm 2003;1:199–202.

5. McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. clin Ther 2003;25:1382–1406.

6. Wheeler G. Gabapentin. Pfizer. curr Opin investig Drugs 2002;3:470–477.

7. Wang PW, Santosa c, Schumacher M, Winsberg M, Strong c, Ketter Ta. Gabapentin augmentation therapy in bipolar depression. Bipolar Depression 2002;4:296–301.

8. Pollack MH, Matthews J, Scott J. Gabapentin as a potential treatment for anxiety disorders. am J Psychiatry 1998; 155:992–993.

9. Moretti r. antonello rM, Torre P, cazzato G. Headache and neck pain: Gabapentin as a possible treatment. J Headache Pain 2000;1:155–161.

10. Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutiric acid on the hyperalgesia observed after thermal injury in the rat. anesth analg 1998;86:348–354.

11. chapman V, Suzuki r, chamarette HL, rygh LJ, Dickenson aH. Effects of systemic carbamazepine and gabapentin on spinal neuronal response in spinal nerve ligated rats. Pain 1998;75:261–272.

12. Shimoyama n, Shimoyama M, Davis aM, inturrisi cE, Elliott KJ. Spinal gabapentin is antinociceptive in the rat formalin test. neurosci Lett 1997;222:65–67.

13. Hansen J, Gilron i, Hong M. The effects of intrathecal gabapentin on spinal morphine tolerance in the rat tail flick and paw pressure tests. anesth analg 2004;99:1180–1184.

14. Donovan-rodriguez T, Dickenson aH, Urch cE. Gabapentin normalizes spinal responses that correlate with behavior in a rat model of cancer-induced bone pain. anesthesiology 2005;102:132–140.

15. atkinson JH, Slater Ma, Williams ra, et al. a placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain 1998;76:287–296.

16. Watson cP, Vernich L, chipman M, reed K. nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. neurology 1998;51:1166–1171.

17. Khoromi S, cui L, nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007;13:66–75.

18. Spiegel K, Kalb r, Pasternak GW. analgesic activity of tricyclic antidepressants. ann neurol 1983;13:462–465.

19. Sawynok J, reid a. antinociception by tricyclic antidepressants in the rat formalin test: Differential effects on different behaviours following systemic and spinal administration. Pain 2001;93:51–59.

20. rojas-corrales MO, casas J, Moreno-Brea Mr, Gib- ert-rahola J, Micó Ja. antinociceptive effects of tricyclic antidepressants and their noradrenergic metabolites. Eur neuropsychopharmacol 2003;13:355–363.

21. Garcia X, Del Valle J, Escribano E, Domenech J, Queralt J. analgesic and antiallodynic effects of antidepressants after infiltration into the rat. Pharmacology 2010;86:216–223.

22. Tallarida rJ. Drug Synergism and Dose-Effect Data analysis. Boca raton, fL: chapman & Hall/crc Press, 2000:59–63.

23. Le Bars D, Gozariu M, cadden SW. animal models of nociception. Pharmacol rev 2001;53:597–652.

24. Luccarini Pa, childeric a, Gayder aM, Voison D, Dallel

r. The orofacial formalin test in the mouse: a behavioral model for studying physiology and modulation of trigeminal nociception. J Pain 2006;7:908–914.

25. raboisson P, Dallel r. The orofacial fortmalin test. neurosci Biobehav rev 2004;28:219–226.

26. Miranda Hf, Sierralta f, Prieto Jc. Synergism between nSaiDs in the orofacial formalin test in mice. Pharmacol Biochem Behav 2009;92:314–318.

27. Miranda Hf, Puig MM, Dursteler c, Prieto Jc, Pinardi G. Dexketoprofen-induced antinociception in animal models of acute pain, synergy with morphine and paracetamol. neuropharmacology 2007;52:291–296.

28. Goldstein a, aronov L, Kalman SM. Principles of Drug action: The basis of Pharmacology, ed 2. new York: John Wiley & Sons, 1974:89–95.

29. cheng JK, chiou Lc. Mechanisms of the antinoceptive action of gabapentin. J Pharmacol Sci 2006;100:471–486.

30. narita n, Kumar n, cherkas PS, et al. Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model. neuroscience 2012;218:359–366.

31. cao Y, Wang H, chiang cY, Dostrovsky JO, Sessle BJ. Pregabalin suppresses nociceptive behavior and central sensitization in a rat trigeminal neuropathic pain model. J Pain 2013;14:193–204.

32. Ventafridda V, Bianchi M, ripamonti c, et al. Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man. Pain 1990;43:155–162.

33. Vu Tn. current pharmacologic approaches to treating neuropathic pain. curr Pain Headache rep 2004;8:15–18.

34. Gilron i, Bailey JM, Tu D, Holden rr, Jackson ac, Houlden rL. nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374:1252–1261.

35. Hughes J, acP Journal club. Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. ann intern Med 2010;152:3–6.

36. Sánchez c, Hyttel J. comparison of the effects of antide- pressants and their metabolites on reuptake of biogen-ic amines and on receptor binding. cell Mol neurobiol 1999;19:467–489.

37. Benbouzid M, choucair-Jaafar n, Yalcin i, et al. chronic, but not acute, tricyclic antidepressant treatment alleviates neuro- ciatic nerve cuffing in mice. Eur J Pain 2008;12:1008–1017.

38. Bohren Y, Karavelic D, Tessier L-H, et al. Mu-opioid receptors are not necessary for nortriptyline treatment of neurophatic allodynia. Eur J Pain 2010;4:700–704.